Macular Degeneration / Macular Disease Trials in Florida, United States

With Florida having a population close to 18 million and approximately 17 percent of this population (approximately 3 million) over the age of 65, well above the national average in the United States, macular degeneration has the potential to be a major health issue for this state.  With macular degeneration being the leading cause of blindness in people over 50, Florida presents a unique opportunity for research and clinical trials, resulting large number of elderly in the state.  With twenty-one active clinical trials in macular degeneration and macular related eye diseases, people suffering from a variety of eye diseases have a unique opportunity to participate in great studies.

With macular degeneration and a variety of other macular related eye diseases having the potential to be a major impact in the State of Florida, and the above average number of elderly in it’s population, there are twenty-one clinical trials are taking place in the state.  These clinical trials in both macular degeneration and macular related eye diseases are being conducted by a variety of organizations, including some of the leading pharmaceutical companies in the world.

In Florida, these clinical trials are actively recruiting participants for a variety of macular related eye diseases including:

  • Macular Degeneration;
  • Macular Edema;
  • Diabetic Macular Edema
  • Retinal Thickening
  • Diabetic Retinopathy; and
  • Central Retinal Vien Occlusion

The details of the clinical trials actively recruiting participants and registered at ClinicalTrials.gov are outlined below:

  1. A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
    Condition: Macular Degeneration
    Intervention: Device: Epi-Rad90 Ophthalmic System | Drug: ranibizumab
    URL: http://ClinicalTrials.gov/show/NCT00454389
  2. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
    Condition: Macular Degeneration
    Intervention: Drug: bevasiranib | Drug: ranibizumab
    URL: http://ClinicalTrials.gov/show/NCT00499590
  3. Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
    Condition: Age Related Macular Degeneration
    Intervention: Drug: ranibizumab | Drug: bevacizumab
    URL: http://ClinicalTrials.gov/show/NCT00593450
  4. Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
    Condition:: Age-Related Macular Degeneration
    Intervention: Drug: POT-4
    URL: http://ClinicalTrials.gov/show/NCT00473928
  5. Double-Masked Study of Efficacy and Safety of IVT VEGF Trap-Eye in Subjects With Wet AMD (VIEW 1)
    Condition:: Neovascular Age-Related Macular Degeneration
    Intervention: Biological: VEGF Trap-Eye|Drug: Comparator
    URL: http://ClinicalTrials.gov/show/NCT00509795
  6. Sensitivity of the Home Macular Perimeter (HMP)
    Condition:: Age Related Macular Degeneration|Choroidal Neovascularization
    Intervention:
    URL: http://ClinicalTrials.gov/show/NCT00604071
  7. An Extension to Study MD7108240
    Condition:: Macular Degeneration
    Intervention: Drug: Pazopanib (5 mg/mL, TID) for 28 days,Pazopanib (2 mg/mL, TID) for 28 days,Pazopanib (5 mg/mL, QD) for 28 days
    URL: http://ClinicalTrials.gov/show/NCT00733304
  8. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
    Condition:: Macular Degeneration
    Intervention: Drug: pazopanib
    URL: http://ClinicalTrials.gov/show/NCT00612456
  9. A Phase 1 Dose Escalation Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD).
    Condition: Age-Related Macular Degeneration
    Intervention: Drug: PF-04523655
    URL: http://ClinicalTrials.gov/show/NCT00725686
  10. Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
    Condition Age-Related Macular Degeneration
    Intervention: Drug: ATG003 (mecamylamine)|Drug: Placebo
    URL: http://ClinicalTrials.gov/show/NCT00607750
  11. A Phase I Trial of a Single Intravitreal Injection of REDD14NP to Patients With CNV Secondary to Wet AMD
    Condition Age-Related Macular Degeneration (AMD)
    Intervention: Drug: REDD14NP
    URL: http://ClinicalTrials.gov/show/NCT00455481
  12. Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-VEGF Treatment in Patients With Age-Related Macular Degeneration
    Condition Choroidal Neovascularization|Age-Related Maculopathy
    Intervention: Drug: Dexamethasone and ranibizumab|Other: Sham injection and ranibizumab
    URL: http://ClinicalTrials.gov/show/NCT00511706
  13. A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
    Condition Macular Edema | Branch Retinal Vein Occlusion
    Intervention: Drug: ranibizumab injection
    URL: http://ClinicalTrials.gov/show/NCT00486018
  14. A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
    Condition Central Retinal Vein Occlusion|Macular Edema
    Intervention: Drug: ranibizumab injection
    URL: http://ClinicalTrials.gov/show/NCT00485836
  15. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE)
    Condition Macular Edema
    Intervention: Drug: Ranibizumab Injection
    URL: http://ClinicalTrials.gov/show/NCT00473330
  16. Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
    Condition Diabetic Retinopathy | Diabetic Macular Edema
    Intervention: Drug: Triamcinolone Acetonide + laser | Drug: Ranibizumab + laser | Drug: Sham injection + laser | Drug: Ranibizumab + deferred laser
    URL: http://ClinicalTrials.gov/show/NCT00444600
  17. A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE)
    Condition Macular Edema
    Intervention: Drug: Ranibizumab Injection
    URL: http://ClinicalTrials.gov/show/NCT00473382
  18. Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
    Condition Proliferative Diabetic Retinopathy | Diabetic Macular Edema
    Intervention: Drug: Ranibizumab|Drug: Triamcinolone Acetonide | Behavioral: Sham injection
    URL: http://ClinicalTrials.gov/show/NCT00445003
  19. Effect of Ruboxistaurin on Clinically Significant Macular Edema
    Condition Diabetic Macular Edema
    Intervention: Drug: ruboxistaurin | Drug: Placebo
    URL: http://ClinicalTrials.gov/show/NCT00133952
  20. Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
    Condition Diabetic Retinopathy | Diabetes Complications
    Intervention: Procedure: Laser Treatment | Drug: PF-04523655 high | Drug: PF-04523655 middle | Drug: PF-04523655 low
    URL: http://ClinicalTrials.gov/show/NCT00701181
  21. Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening
    Condition Cystoid Macular Edema | Retinal Thickening
    Intervention: Drug: 2. Xibrom (Bromfenac)|Drug: 1. Pred Forte
    URL: http://ClinicalTrials.gov/show/NCT00469781

These clinical trials in macular degeneration and macular related eye diseases may have certain conditions and restrictions placed upon the participants.

Speak Your Mind

*